Piramal Pharma, a leading global pharmaceutical company, has announced the expansion of its biologics manufacturing infrastructure to cater to the growing demand for biologic therapies. The company has invested in upgrading its facilities and capabilities to enhance its biologics manufacturing services, including process development, scale-up, and commercial production.
The expansion is part of Piramal Pharma’s strategy to strengthen its position as a trusted partner for biopharmaceutical companies, providing end-to-end services for the development and manufacture of biologics. The company’s biologics business has been growing rapidly, driven by the increasing demand for biologic therapies to treat a range of diseases, including cancer, autoimmune disorders, and genetic disorders.
Piramal Pharma’s biologics manufacturing infrastructure is designed to meet the highest standards of quality, safety, and regulatory compliance. The company’s facilities are equipped with state-of-the-art equipment and technology, including single-use bioreactors, chromatography systems, and fill-finish lines. The company has also implemented advanced process control systems and quality management systems to ensure that its biologics products meet the required standards of quality and purity.
The expansion of Piramal Pharma’s biologics manufacturing infrastructure includes the addition of new production lines, laboratories, and process development facilities. The company has also hired a team of experienced biologics manufacturing professionals, including process engineers, quality assurance specialists, and regulatory experts. This team will work closely with clients to develop and manufacture biologics products that meet their specific needs and requirements.
Piramal Pharma’s biologics manufacturing services include cell line development, process development, scale-up, and commercial production. The company also offers a range of analytical and testing services, including bioanalytical testing, immunogenicity testing, and stability testing. The company’s biologics products are designed to meet the needs of a range of therapeutic areas, including oncology, immunology, and rare diseases.
The expansion of Piramal Pharma’s biologics manufacturing infrastructure is expected to have a significant impact on the biopharmaceutical industry, enabling the company to meet the growing demand for biologic therapies and providing biopharmaceutical companies with a trusted partner for the development and manufacture of biologics. With its enhanced capabilities and infrastructure, Piramal Pharma is well-positioned to play a key role in the development of new biologic therapies and the treatment of a range of diseases. Overall, the expansion is a significant step forward for Piramal Pharma and is expected to drive growth and innovation in the biopharmaceutical industry.